By adding PARP1-i and applying a (modest) RT/cDDP dose reduction in those treatment regimens, we might achieve an improvement in the tumor control combined with a reduction of toxicity and occurrence of severe side effects. This evidence concerns the gene PARP1 and neoplasm.